Tesamorelin 10mg
FDA-Approved GHRH for Visceral Fat Reduction and GH Research
Tesamorelin (Egrifta) is an FDA-approved GHRH analogue for HIV-associated lipodystrophy that reduces visceral adipose tissue by 15-20% while increasing IGF-1. It has a longer half-life than Sermorelin and is the only GHRH analogue with Phase 3 clinical approval for fat reduction.
FDA-Approved GHRH for Visceral Fat Reduction and GH Research
Tesamorelin contains full GHRH(1-44) activity with a trans-3-hexenoic acid modification for enhanced stability. Clinical trials show 15-20% visceral fat reduction, making it the most clinically validated GHRH for metabolic and body composition research.
As one of the most studied compounds in the growth & body comp research space, Tesamorelin has attracted sustained scientific interest across Visceral fat research, Metabolic body composition studies, GH/IGF-1 restoration research. Peer-reviewed evidence indicates that fDA-approved (Egrifta) for visceral fat reduction, which has positioned Tesamorelin as a reference standard for researchers exploring visceral fat research outcomes. The compound's selectivity and documented tolerability in preclinical models have contributed to a rapidly growing body of literature over the past decade.
Tesamorelin Documented Benefits: 3 Documented Mechanisms
Visceral Fat Reduction
Reduces visceral adipose tissue 15-20% in clinical trials for HIV-associated lipodystrophy.
GH/IGF-1 Restoration
Increases GH pulse amplitude and IGF-1 levels toward youthful ranges.
FDA-Approved
Phase 3 clinical validation provides the most evidence-based GHRH for metabolic research.
How Tesamorelin Works: Molecular Mechanism & Pathway
Modified GHRH(1-44) analogue activating pituitary GHRH-R for GH secretion; downstream IGF-1 and lipolysis effects reduce visceral adiposity via GH-driven fat mobilization.
The 3 primary research pathways identified for Tesamorelin — Visceral Fat Reduction, GH/IGF-1 Restoration, FDA-Approved — collectively point to a compound with pleiotropic activity across interconnected biological systems. Studies have further shown that 15-20% VAT reduction in clinical trials, reinforcing the mechanistic picture established in earlier cell-line work. Unlike single-pathway agents, Tesamorelin's broad receptor engagement profile continues to generate hypotheses for novel applications beyond its originally characterized use cases.
Research Protocols & Compound Combinations
Tesamorelin is routinely studied alongside CJC-1295 DAC and Tesamorelin in growth & body comp-focused compound panels. Researchers investigating visceral fat research have found that pairing compounds with complementary receptor profiles can produce additive results while keeping individual doses within well-characterized ranges. Preliminary evidence that phase 3 evidence for metabolic body composition research has informed several of these multi-compound protocol designs.
Purity, Testing & Research Grade Standards
All Tesamorelin research material offered through this catalog is manufactured under controlled conditions and independently verified by a third-party laboratory prior to release. Each lot undergoes High-Performance Liquid Chromatography (HPLC) analysis to confirm ≥98% purity, with identity confirmed via mass spectrometry. The accompanying Certificate of Analysis (CoA) documents the exact purity, molecular weight confirmation, and lot-specific testing date — data that should accompany any reproducible research protocol. Lyophilized powder formulation ensures maximum stability during shipping and storage at −20°C long-term or 4°C for short-term use.
◈ Key Highlights
- FDA-approved (Egrifta) for visceral fat reduction
- 15-20% VAT reduction in clinical trials
- Phase 3 evidence for metabolic body composition research
Ideal For
- Visceral fat research
- Metabolic body composition studies
- GH/IGF-1 restoration research
- HIV lipodystrophy models
Intended for laboratory use only. Not for human or animal consumption. Not FDA approved. Handle in appropriate lab settings only.
What the Research Shows
The following data points are derived from peer-reviewed preclinical and clinical studies on Tesamorelin. All studies cited in compound profiles are indexed in PubMed or published in peer-reviewed journals.
FDA-approved (Egrifta) for visceral fat reduction
15-20% VAT reduction in clinical trials
Phase 3 evidence for metabolic body composition research
Third-Party Verified Every Batch
Each vial of Tesamorelin is independently tested by a third-party laboratory before fulfillment. You receive the actual CoA (Certificate of Analysis) documentation with your order.
